You
are here: Home: BCU 5|2003: Paul
E Goss, MD, PhD, FRCP(CA),
FRCP(UK): Select publications
Select publications
Publications discussed by Dr Goss
Arpino G et al. ErbB-2 amplification, ErbB-1 expression and tamoxifen
response in ER-positive
metastatic breast cancer; A SWOG study. Breast Cancer Res Treat 2002:Abstract
232.
Dirix LY et al. Open-label, multi-center, controlled study of exemestane
(E-Aromasin®)
with or
without celecoxib (Cx - Celebrex®) in postmenopausal women with advanced
breast cancer (ABC)
progressed on tamoxifen (T). Breast Cancer Res Treat 2002:Abstract
269.
Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy
than tamoxifen for ErbB-1-
and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence
from a phase III
randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract
Shou J et al. Blockade of the estrogen receptor/growth factor cross-talk
implicated in breast cancer
tamoxifen resistance using a selective EGFR TK inhibitor. Breast Cancer Res
Treat 2002:Abstract
246.
Siris E et al. Effects of raloxifene on fracture severity in postmenopausal
women with osteoporosis:
Results from the MORE study. Osteoporos Int 2002:13;907-13. Abstract
|
